Influence of yttrium aluminum garnet laser posterior capsulotomy opening size on intraocular pressure and central macular thickness

2019 ◽  
Vol 20 (4) ◽  
pp. 157
Author(s):  
AhmedA Alhagaa ◽  
NermeenM Badawi
2017 ◽  
Vol 11 (2) ◽  
pp. 63-66 ◽  
Author(s):  
Asaf Achiron

ABSTRACT Aim The current treatment for posterior capsular opacification (PCO), neodymium-doped yttrium aluminum garnet (Nd:YAG) laser capsulotomy, may lead to increased intraocular pressure (IOP). Our aim was to survey routines in the management of IOP spikes and to identify the rate of IOP spikes following prophylactic apraclonidine treatment. Materials and methods A survey questionnaire among ophthalmologists and a retrospective registry review was used. Patients were administered apraclonidine 0.5% prior to capsulotomy. The IOP was measured before and 1 hour postprocedure. Results A total of 71% of responders (n = 45) routinely prescribe topical IOP-lowering medication and 82% routinely measure IOP before or after capsulotomy. The registry analysis included 87 eyes of 75 patients. Mean IOP decreased by 0.9 ± 3.3 mm Hg (p = 0.01, range: −6 to 10) following capsulotomy. No patient reached IOP values above 21 mm Hg following the procedure, with 3.4 and 1.1% of patients demonstrating an IOP elevation of more than 3 and 5 mm Hg respectively. No association was found between number of laser shots, mean laser power, or comorbid conditions, such as diabetes, hypertension, or glaucoma status with posttreatment IOP. Conclusion Most ophthalmologists surveyed routinely prescribe prophylactic IOP-lowering medication and measure IOP before or after capsulotomy. Mean IOP remained clinically stable following capsulotomy with prophylactic apraclonidine instillation, and no patient reached IOP values above 21 mm Hg. Differences in laser delivery or comorbid conditions were not associated with posttreatment IOP. Considering that no patient demonstrated a clinically significant IOP spike following prophylactic apraclonidine instillation, perhaps routine measurement of IOP following primary Nd:YAG laser may be reserved for high-risk patients only. Clinical significance In this work, we showed the prophylactic effect of apraclonidine 0.5% and suggest that measuring IOP after the procedure is necessary only in certain high-risk cases, possibly helping to reduce workload and patient waiting time and improving quality of service. How to cite this article Achiron A. Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel. J Curr Glaucoma Pract 2017;11(2):63-66.


2021 ◽  
Vol 52 (11) ◽  
pp. 610-613
Author(s):  
Ryan A. Shields ◽  
Olivia T. Cheng ◽  
Alan J. Ruby ◽  
George A. Williams ◽  
Jeremy D. Wolfe

2017 ◽  
Vol 9 (2) ◽  
pp. 30-34 ◽  
Author(s):  
En Hyung Kim

Partial unilateral lentiginosis (PUL) is an unusual pigmentary disorder characterized by numerous lentigines grouped within an area of normal skin. Although treatment is not necessary, many patients with facial PUL seek medical help for cosmetic reasons. There is no established standard treatment for PUL. Conventional lasers may cause postinflammatory hyperpigmentation because keratinocytes are injured during the process. Also, scarring, long downtime, and pain are important issues. A 19-year-old patient with facial PUL was successfully treated with low-fluence 1,064-nm Q-switched neodymium-doped yttrium aluminum garnet (QS Nd:YAG) laser. Although the exact mechanism by which low-fluence 1,064-nm QS Nd:YAG laser improves pigmentary lesions is unclear, the terms “subcellular selective photothermolysis” and “melanocyte apoptosis and replacement” have been proposed. If appropriate measures are taken to monitor patient response during and after the procedure, low-fluence 1,064-nm QS Nd:YAG laser may achieve good cosmetic results in the treatment of PUL with a very safe and effective profile.


Sign in / Sign up

Export Citation Format

Share Document